Research Study

STAR: A Phase 2, Multicenter, Randomized, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia
Principal Investigator 
Kevin Gregory-Evans

Overview

Body Locations and Systems 
Eye Disorders
ClinicalTrials.gov# 
NCT02647359
Status 
Recruiting
Study Start/End 
Jan 21, 2016 to Jan 31, 2018
Locations 
Vancouver General Hospital
Name/Title 
Cheryl Gregory-Evans, Professor
Phone 
604-875-5529
Email Address 
cge30@mail.ubc.ca
Purpose of Study 

This is a Phase 2, randomized, double-masked, placebo-controlled study of ataluren in patients with aniridia caused by a nonsense mutation. Patients will receive masked study drug for 48 weeks followed by open-label ataluren for another 48 weeks. Safety and efficacy will be assessed.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.